Actinium Pharmaceuticals, Inc. insider trading

Every open-market purchase and sale by Actinium Pharmaceuticals, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Actinium Pharmaceuticals, Inc.’s insiders pay?

From April 18, 2016 to August 4, 2017, 4 insiders reported 4 open-market purchases and 13 sales not made under a pre-set plan in Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Memorial Sloan-Kettering Cancer Center	10% owner	0	—	—	13	—	September 1, 2016
Seth Sandesh	Chairman & CEO	2	—	—	0	—	August 4, 2017
Dave Kaushik J	CEO and Interim CFO	1	—	—	0	—	April 18, 2016
Nicholson, C. David	Director	1	—	—	0	—	April 18, 2016

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Actinium Pharmaceuticals, Inc. · Funds · Politicians